Tuesday 20 October, 2009

Glatiramer acetate 20 mg/ml injection (Copaxone): Teva sued Mylan

Refer to our earlier post Here, wherein, we reported the ANDA filing by generic player Mylan (with Para IV certification) against Glatiramer acetate 20 mg/ml injection (Copaxone).

As expected, innovator Teva has reported Here that it has filed a lawsuit against Mylan Pharma and it's API supplier Natco Pharma for patent infringement in the U.S. District Court for the Southern District of New York.

Innovator Teva has listed US5981589, US6054430, US6342476, US6362161, US6620847, US6939539 and US7199098 patents in Orange Book for Glatiramer acetate 20 mg/ml injection (Copaxone). The said patents would expire on May 24, 2014. As per complaint filed in in the U.S. District Court for the Southern District of New York, Teva has requested court to block the generic version’s approval till May 24, 2014.

Earlier, innovator has sued generic players Momenta and Sandoz in U.S. District Court for the Southern District of New York for filing ANDA in Jul, 2008.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker